---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-211584"
form_type: "8-K"
ticker: "COGT"
cik: "0001622229"
company_name: "Cogent Biosciences, Inc."
filed_at: "2024-09-03T23:59:59+00:00"
generated_at: "2026-05-31T06:38:05.661265+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Cogent Biosciences completes PEAK trial enrollment and advances past interim futility analysis

## Summary
- Phase 3 PEAK trial enrolled 413 GIST patients, exceeding target; top-line results expected by end of 2025.
- Independent Data Monitoring Committee recommended continuing PEAK study after pre-planned interim futility analysis.
- SUMMIT trial in NonAdvSM now expects to complete enrollment in Q1 2025, three months earlier than projected.
- Darara Dibabu appointed VP of Marketing; granted inducement award of 100,000 stock options at $10.74 per share.
- Bezuclastinib combination with sunitinib for second-line GIST is primary focus of registration-directed trials.

## SEC filing metadata
- accession: 0001193125-24-211584
- form_type: 8-K
- ticker: COGT
- cik: 0001622229
- company_name: Cogent Biosciences, Inc.
- filed_at: 2024-09-03T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1622229/000119312524211584/0001193125-24-211584-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1622229/000119312524211584/d873439d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-211584
- JSON: https://secwatch.observer/filing/0001193125-24-211584.json
- Plain text: https://secwatch.observer/filing/0001193125-24-211584.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.